Discovery of Imidazo[1,2- b ]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitors
Journal of Medicinal Chemistry · 12.06.2025 · 68 (11) · 10897-10929
DOI: 10.1021/acs.jmedchem.4c03083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.05.2025. Verfasst von Dandan Zhang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Centre of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Mi…. Hauptthemen laut MEDLINE: Agammaglobulinaemia Tyrosine Kinase, Pyridazines, Protein Kinase Inhibitors, Drug Discovery. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Education Department of Henan Province, Science and Technology Innovation Talents in Universities of Henan Province, Henan Normal University.
Abstract (Originalsprache)
Bruton's tyrosine kinase (BTK) is a crucial enzyme in the B cell receptor signaling pathway. It plays a central role in B cell development, maturation, and signaling. This role extends to the survival, proliferation, and migration of malignant B cells, making BTK an intriguing target in the search for therapeutics against B cell malignancies. Our research focused on the discovery of a covalent inhibitor of BTK with good selectivity and potency and a favorable safety profile. We identified compound 22, an imidazo[1,2-b]pyridazine derivative, exhibiting potent BTK inhibition (IC50 1.3 nM) with excellent selectivity across 310 kinases. Compound 22 demonstrated favorable pharmacokinetics and a robust safety profile. In a xenograft model, it significantly inhibited tumor growth, achieving complete tumor regression in 7 out of 10 mice at a dose of 15 mg/kg. This promising preclinical data led to the advancement of compound 22, named TM471-1, into Phase I clinical trials (CXHL2300956).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Centre of Henan Province for Green Manufacturing of Fine Chemicals, Key Laboratory of Green Chemical Media and Reactions, Ministry of Education, Henan Engineering Research Centre of Chiral Hydro…
- Henan Zhiwei Biomedicine Co., Ltd., Xinxiang, Henan 453007, China.
- Key Laboratory of Artificial Intelligence and Personalized Learning in Education of Henan Province, College of Computer and Information Engineering, Henan Normal University, Xinxiang, Henan 453007, China.
ORCID-Profile: Shouning Yang, Chunhua Ma
Förderung
- Education Department of Henan Province
- Science and Technology Innovation Talents in Universities of Henan Province
- Henan Normal University
- National Natural Science Foundation of China
- Henan Provincial Science and Technology Research Project
Zitieren
APA
Zhang, D., Zhao, J., Xu, G., Wang, Y., Li, Y., Ren, H., Geng, J., Du, Y., Zhang, C., Yang, S., Liu, D., Gao, J., Xiong, Y., Zhang, H., Li, W., Wang, W., Wang, D., Li, B., He, X., …, & Ding, Q. (2025). Discovery of Imidazo[1,2- b ]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitors. Journal of Medicinal Chemistry, 68(11), 10897-10929. https://doi.org/10.1021/acs.jmedchem.4c03083
Vancouver
Zhang D, Zhao J, Xu G, Wang Y, Li Y, Ren H, et al. Discovery of Imidazo[1,2- b ]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitors. Journal of Medicinal Chemistry. 2025;68(11):10897-10929. doi:10.1021/acs.jmedchem.4c03083
BibTeX
@article{Zhang2025,
author = {Zhang, Dandan and Zhao, Jie and Xu, Guiqing and Wang, Yue and Li, Yang and Ren, Hanxiao and Geng, Jiajun and Du, Yu and Zhang, Chenchen and Yang, Shouning and Liu, Dongfang and Gao, Jiajing and Xiong, Yi and Zhang, Haoyi and Li, Wei and Wang, Wei and Wang, Di and Li, Biao and He, Xing and Ma, Chunhua and Jiang, Yuqin and Ding, Qingjie},
title = {Discovery of Imidazo[1,2- b ]pyridazine Derivatives as Potent and Highly Selective Irreversible Bruton’s Tyrosine Kinase (BTK) Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {11},
pages = {10897--10929},
doi = {10.1021/acs.jmedchem.4c03083}
}
EUVIMED